Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

CTXR Citius Pharmaceuticals Inc. Common
$0.59 -2.38% -0.01
Notify me if price changes either direction
Interactive Brokers Logotype

Buy CTXR stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 16.1M
Enterprise value 16.0M
Trailing PE -0.174378696278
Forward PE -0.41791666
PEG Ratio 0.0069206545085332
Enterprise to EBITDA -0.41860815281123
Enterprise to revenue 2.251
Price to book MRQ 0.24806266
Price to sales TTM 2.3251934

Financials

Fiscal Year Ends 2025-09-30
Most Recent Quarter (MRQ) 2026-03-31
Revenue (TTM) 7.1M
Diluted EPS TTM -1.75
Total Cash (MRQ) 17.0M
Current ratio (MRQ) 0.839
Operating Cash Flow (TTM) -34867204

CTXR trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent CTXR News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.